{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Eflornithine&page=2", "query": { "intervention": "Eflornithine", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Eflornithine&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-28T16:22:56.199Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05879367", "title": "Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma, IDH-wildtype", "Glioblastoma", "Glioblastoma Multiforme", "Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype", "GBM", "Astrocytoma", "Astrocytoma, IDH-Mutant" ], "interventions": [ { "name": "Eflornithine (Dose Level -1)", "type": "DRUG" }, { "name": "Eflornithine (Dose Level 2)", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Orbus Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2023-07-24", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2025-06-25", "last_synced_at": "2026-09-28T16:22:56.199Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Detroit, Michigan • New York, New York + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05879367" }, { "nct_id": "NCT00118365", "title": "Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Precancerous Condition" ], "interventions": [ { "name": "placebo", "type": "OTHER" }, { "name": "eflornithine", "type": "DRUG" }, { "name": "sulindac", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 375, "start_date": "1998-07", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2015-01-22", "last_synced_at": "2026-09-28T16:22:56.199Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00118365" }, { "nct_id": "NCT00176995", "title": "Effect of 15% Eflornithine Hydrochloride Cream on African-American Males With Pseudofolliculitis Barbae", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pseudofolliculitis Barbae" ], "interventions": [ { "name": "15% Eflornithine Hdyrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hordinsky, Maria K., MD", "sponsor_class": "INDIV", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 15, "start_date": "1999-03", "completion_date": "2000-10", "has_results": false, "last_update_posted_date": "2006-11-13", "last_synced_at": "2026-09-28T16:22:56.199Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00176995" }, { "nct_id": "NCT07321912", "title": "Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Osteosarcoma", "Ewing Sarcoma" ], "interventions": [ { "name": "Eflornithine", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "0 Years to 50 Years" }, "enrollment_count": 406, "start_date": "2026-06-05", "completion_date": "2036-06-01", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-09-28T16:22:56.199Z", "location_count": 2, "location_summary": "Tampa, Florida • Hershey, Pennsylvania", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07321912" }, { "nct_id": "NCT01059071", "title": "Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "DFMO", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Giselle Sholler", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 21, "start_date": "2010-02", "completion_date": "2015-05", "has_results": true, "last_update_posted_date": "2024-08-06", "last_synced_at": "2026-09-28T16:22:56.199Z", "location_count": 7, "location_summary": "Orange, California • Hartford, Connecticut • Orlando, Florida + 4 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01059071" }, { "nct_id": "NCT04696029", "title": "DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Medulloblastoma" ], "interventions": [ { "name": "Difluoromethylornithine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Giselle Sholler", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 118, "start_date": "2021-03-29", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-09-28T16:22:56.199Z", "location_count": 25, "location_summary": "Little Rock, Arkansas • Oakland, California • Sacramento, California + 22 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Oakland", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04696029" }, { "nct_id": "NCT05717153", "title": "Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Diffuse Glioma", "Malignant Glioma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Eflornithine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Polyamine Transport Inhibitor AMXT-1501 Dicaprate", "type": "DRUG" }, { "name": "Resection", "type": "PROCEDURE" }, { "name": "Microdialysis", "type": "DEVICE" }, { "name": "Placement", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "DEVICE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2023-10-01", "completion_date": "2027-09-15", "has_results": false, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-09-28T16:22:56.199Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05717153" }, { "nct_id": "NCT03536728", "title": "Oral AMXT 1501 Dicaprate in Combination With DFMO", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Solid Tumor", "Solid Carcinoma", "Advanced Cancer" ], "interventions": [ { "name": "AMXT1501", "type": "DRUG" }, { "name": "DFMO", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aminex Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 56, "start_date": "2018-06-12", "completion_date": "2023-04-21", "has_results": false, "last_update_posted_date": "2023-05-25", "last_synced_at": "2026-09-28T16:22:56.199Z", "location_count": 4, "location_summary": "Austin, Texas • Houston, Texas • San Antonio, Texas + 1 more", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03536728" }, { "nct_id": "NCT05500508", "title": "Oral AMXT 1501 Dicaprate in Combination With IV DFMO", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Solid Tumor", "Solid Carcinoma", "Advanced Cancer", "DIPG Brain Tumor", "Ovary Cancer", "Breast Cancer", "Papillary Thyroid Cancer", "Head and Neck Cancer", "Gastric Cancer", "Nsclc", "Mesotheliomas Pleural", "Mesothelioma Peritoneum", "Esophageal Cancer", "Diffuse Midline Glioma, H3 K27M-Mutant", "Endometrial Cancer", "Cervical Cancer", "Melanoma", "Colorectal Cancer", "Glioma, Malignant" ], "interventions": [ { "name": "AMXT1501", "type": "DRUG" }, { "name": "DFMO", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aminex Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 15, "start_date": "2022-11-29", "completion_date": "2024-12-12", "has_results": false, "last_update_posted_date": "2024-12-24", "last_synced_at": "2026-09-28T16:22:56.199Z", "location_count": 6, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05500508" }, { "nct_id": "NCT00003814", "title": "Eflornithine in Treating Patients With Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "eflornithine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 450, "start_date": "1999-02", "completion_date": "2007-05", "has_results": false, "last_update_posted_date": "2013-12-18", "last_synced_at": "2026-09-28T16:22:56.199Z", "location_count": 61, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Anaheim, California + 49 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Glendora", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003814" } ] }